Novel Therapeutics and Treatment Strategies for Medullary Thyroid Cancer.
Immunotherapy
Medullary thyroid carcinoma
Neoadjuvant therapy
RET mutation
Surgery
Journal
Endocrinology and metabolism clinics of North America
ISSN: 1558-4410
Titre abrégé: Endocrinol Metab Clin North Am
Pays: United States
ID NLM: 8800104
Informations de publication
Date de publication:
06 2022
06 2022
Historique:
entrez:
6
6
2022
pubmed:
7
6
2022
medline:
9
6
2022
Statut:
ppublish
Résumé
Medullary thyroid cancer is a rare thyroid malignancy with unique management considerations. In general, small intrathyroidal tumors are cured by total thyroidectomy with central compartment dissection, while large tumors and those with disease spread to regional lymph nodes and distant organs (most commonly lung, liver, and bone) are more difficult to cure. The last decade has seen significant progress in the treatment of advanced MTC, largely due to the discovery and availability of novel targeted therapies, including new drugs specifically targeting the RET protooncogone.
Identifiants
pubmed: 35662447
pii: S0889-8529(22)00006-8
doi: 10.1016/j.ecl.2022.02.001
pii:
doi:
Substances chimiques
Proto-Oncogene Proteins c-ret
EC 2.7.10.1
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
379-389Informations de copyright
Published by Elsevier Inc.
Déclaration de conflit d'intérêts
Disclosure E. Walgama: none. N. Busaidy: none. Dr. Zafereo receives industry support for clinical trials from Eli Lilly